Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses

Leukemia and Lymphoma

Volumn 46, Issue 4, 2005, Pages 571-580

  Mundhada, Shailendra ^a   Shaw, Joanne ^a   Mori, Shahram ^a   Savary, Cherylyn A ^a   Mullen, Craig A ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Graft vs. host disease; Graft vs. leukemia; Leukemia; T cell depletion; Transplantation; Tumor immunity; Vaccination

Indexed keywords

CYTOKINE; MINOR HISTOCOMPATIBILITY ANTIGEN; TUMOR VACCINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASSAY; CONTROLLED STUDY; CYTOLYSIS; DONOR; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HOST; HYPOTHESIS; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECIPIENT; SURVIVAL; T CELL DEPLETION; T LYMPHOCYTE; THYMUS FUNCTION;

ANIMALS; BONE MARROW TRANSPLANTATION; CANCER VACCINES; CELL LINE; DISEASE MODELS, ANIMAL; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HISTOCOMPATIBILITY ANTIGENS; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 17844380304     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500032596     Document Type: Article

References (27)

1. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041-2050.
2. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989;320:828-834.
3. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991;78:2120-2130.
4. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995;345:1144-1146.
5. van der Straaten HM, Fijnheer R, Dekker AW, Nieuwenhuis HK, Verdonck LF. Relationship between graft-versus-host disease and graft-versus-leukaemia in partial T cell-depleted bone marrow transplantation. Br J Haematol 2001;114:31-35.
6. Lee CK, deMagalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3 + T-cell-depleted graft. Bone Marrow Transplant 2003;31:121-128.
7. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999;93:2336-2341.
8. Greten TF, Jaffee EM. Cancer vaccines. J Clin Oncol 1999;17:1047-1060.
9. Dickinson AM, Wang XN, Sviland L, Vyth-Dreese FA, Jackson GH, Schumacher TN, Haanen JB, Mutis T, Goulmy E. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002;8:410-414.
10. Anderson LD, Savary CA, Mullen CA. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. Blood 2000;95:2426-2433.
11. Zoller M. Tumor vaccination after allogeneic bone marrow cell reconstitution of the nonmyeloablatively conditioned tumor-bearing murine host. J Immunol 2003;171:6941-6953.
12. Korngold R, Sprent J. Variable capacity of L3T4 + T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J Exp Med 1987;165:1552-1564.
13. Green MC, Witham BA. Handbook on genetically standardized Jax mice. 4th ed. Bar Harbor, Maine: Jackson Laboratory; 1991.
14. Kernan NA. T-cell depletion for the prevention of graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic cell transplantation. Malden, Massachusetts: Blackwell Science; 1999. p 186-196.
15. Restifo NP, Esquivel F, Asher AL, Stotter H, Barth RJ, Bennick JR, Mule JJ, Yewdell JW, Rosenberg SA. Defective presentation of endogenous antigens by a murine sarcoma: implications for the failure of an anti-tumor immune response. J Immunol 1991;147:1453-1459.
16. Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 1992;356:443-446.
17. Sanburn N, Cornetta K. Rapid titer determination using quantitative real-time PCR. Gene Ther 1999;6:1340-1345.
18. Eden PA, Christianson GJ, Fontaine P, Wettstein PJ, Perreault C, Roopenian DC. Biochemical and immunogenetic analysis of an immunodominant peptide (B6dom1) encoded by the classical H7 minor histocompatibility locus. J Immunol 1999;162:4502-4510.
19. Perreault C, Jutras J, Roy DC, Filep JG, Brochu S. Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease. J Clin Invest 1996;98:622-628.
20. Anderson LD, Mori S, Mann S, Savary CA, Mullen CA. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease. Cancer Res 2000;60:5797-5802.
21. Anderson LJ, Petropoulos D, Everse LA, Mullen CA. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine. Cancer Res 1999;59:1525-1530.
22. Godthelp BC, van Tol MJ, Vossen JM, van Den Elsen PJ. T-cell immune reconstitution in pediatric leukemia patients after allogeneic bone marrow transplantation with T-cell-depleted or unmanipulated grafts: evaluation of overall and antigen-specific T-cell repertoires. Blood 1999;94:4358-4369.
23. Lamb LS Jr, Henslee-Downey PJ, Parrish RS, Godder K, Thompson J, Lee C, Gee AP. Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother 1996;5:503-509.
24. Lamb LS Jr, Gee AP, Henslee-Downey PJ, Geier SS, Hazlett L, Pati AR, Godder K, Abhyankar SA, Turner MW, Lee C et al. Phenotypic and functional reconstitution of peripheral blood lymphocytes following T cell-depleted bone marrow transplantation from partially mismatched related donors. Bone Marrow Transplant 1998;21:461-471.
25. Teshima T, Mach N, Hill GR, Pan L, Gillessen S, Dranoff G, Ferrera JL. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res 2001;61:162-171.
26. Hakim FT, Cepeda R, Kaimei S, Mackall CL, McAtee N, Zujewski J, Cowan K, Gress RE. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 1997;90:3789-3798.
27. Mackall CL, Gress RE. Thymic aging and T-cell regeneration. Immunol Rev 1997;160:91-102.